Catus Consult ApS: Financial statements 2021
CVR: 39791633
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Catus Consult ApS (CVR 39791633) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK 23,256 the year before. Equity in the 2021 report amounted to DKK 40,000. The solvency ratio was 100%.
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 0
- Equity
- DKK 40,000
- Total Assets
- DKK 40,000
Official annual report
Find more companies like Catus Consult ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
On September 24, 2021, the company changed its name from Isanans Pharma IVS to Isanans Pharma ApS.
Catus Consult ApS has published its annual report for 2020. Gross profit came to DKK 30,050, and the net result was DKK 23,256.
About Catus Consult ApS
Catus Consult ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2018. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Isanans Pharma ApS and Isanans Pharma IVS. The management consists of Kamilla Rolsted. The company is owned by VAMI Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 680,675 and a net result of DKK 137,824 compared with DKK -7,234 the year before. Equity in the 2025 report amounted to DKK 181,118.